Clinical Trials

Searchable database of currently enrolling clinical trials

Imaging and Therapy for Prostate-Specific Membrane Antigen (PSMA) Low-Expressing Prostate Cancers; Could Gastrin-Releasing Peptide Receptor (GRPR) Be the Next Target?

Evan Y. Yu
July 24, 2023

PSMA is all the craze in the field of prostate cancer. We now sensitively image PSMA on prostate cancer with using various PET imaging radiotracers. We also are therapeutically targeting PSMA using radioligand therapy, with the regulatory approval of 177Lutetium-PSMA-617 as the first example of this class of agents.1 This is likely the first of many other PSMA-targeted radioligand therapies. Yet, many other viable mechanisms of therapeutic targeting of PSMA are currently being explored with antibody-drug conjugates, bispecific antibodies, and even CAR-T cell therapeutics.

READ MORE PREVIOUS ARTICLES

Dr. Evan Yu, MD

Evan Y. Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
  • Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
  • Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.